

March 2, 2020

To: All Concerned Parties

Company Name: Solasia Pharma K.K.  
Representative: Yoshihiro Arai, President & CEO  
(Code number: 4597, TSE Mothers Section)  
Contact: Toshio Miyashita, CFO, Director  
Tel: 81-3-5843-8049

## PledPharma Announces Update on SP-04 (PledOx®) Clinical Study Information

PledPharma AB (“Pled”), Solasia’s partner announced today regarding update on SP-04 (PledOx®) phase III clinical study. For more information, please refer to following URL link to Pled website.

[https://www.pledpharma.com/mfn\\_news/pledpharma-places-dosing-of-patients-in-the-polar-program-on-hold/](https://www.pledpharma.com/mfn_news/pledpharma-places-dosing-of-patients-in-the-polar-program-on-hold/)

Pled has received orders from multiple authorities (FDA and ANSM) to stop recruitment and dosing of patients. Pled has taken a decision to place dosing of patients in the POLAR program on hold in all countries. Solasia has also decided to support Pled's decision.

Pled will provide detailed safety information to the FDA and ANSM, and will work with these authorities to lift the clinical trial suspension order. Upon lifting of the order, Pled and Solasia plan to recruit patients and resume study drug administration in all countries.

Solasia expects this event would only have a marginal impact on the earnings forecast for the current fiscal year, and hence no change has been made to the forecast.

###